What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings

Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks Investment Research • 10 hours ago

Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline

Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review

GlobeNewsWire • Oct 27, 2026

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.

Seeking Alpha • Oct 26, 2026

Teva to Host R&D Day on Wednesday, November 11 in New York City

TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leadership will discuss its R&D pipeline, its near-term value-creation potential over the next five years, and Teva's ongoing transformation into an innovative biopharma company through the Pivot to Growth strategy.

GlobeNewsWire • Oct 12, 2026

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

Zacks Investment Research • Oct 12, 2026

Teva wins FDA approval for monthly schizophrenia injection Weltruza

Teva said on Friday it ​had received approval ‌from the US Food and Drug ​Administration for ​its Weltruza drug for ⁠extended-release injectable suspension ​as the first ​and only once-monthly subcutaneous injectable olanzapine for ​adults with schizophrenia.

Reuters • Oct 9, 2026

Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval

Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease.

Investors Business Daily • Oct 9, 2026

Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA

Teva Pharmaceutical Industries NYSE: TEVA said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for schizophrenia.

MarketBeat • Oct 9, 2026

FDA Approves Teva's New Once-Monthly Schizophrenia Injection

The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to market Weltruza, a once-monthly subcutaneous injectable for adult patients with schizophrenia.

Benzinga • Oct 9, 2026

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript

Seeking Alpha • Oct 9, 2026